{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:37:40Z","timestamp":1792485460536,"version":"4.5.0"},"reference-count":243,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n In the absence of a commonly accepted definition, conversion surgery is generally considered as surgical resection with the intent of prolonging survival after non-surgical induction therapy in patients with upfront unresectable disease at diagnosis. Despite the heterogeneity of possible targets, conversion surgery is a quickly evolving concept, with commonalities for upper gastrointestinal (UGI) and hepato-pancreato-biliary (HPB) malignancies.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A comprehensive narrative review of the most recent and relevant literature was conducted by experts in the field of different UGI and HPB tumours.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The increased interest of the surgical scientific community in the concept of conversion surgery can be explained by the continuous improvements in non-surgical therapies aimed at controlling the systemic tumour burden and the local extension of cancer, supported by improvements in surgical outcomes for advanced resections in expert centres. The toolbox of the surgical oncologist seeking conversion in the case of unresectable UGI and HBP tumours is large and includes (but is not limited to) systemic chemotherapy, (chemo)radiation, targeted therapy\/immunotherapy, locoregional ablation techniques, intra-arterial therapies, liver hypertrophy induction techniques, treatments of underlying medical conditions, and prehabilitation.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Conversion surgery represents a powerful instrument to prolong the survival of patients with unresectable UGI and HPB malignancies. However, most of the available evidence is of a low level and at very high risk of selection bias. Alongside a profound understanding of (and respect for) the biology of cancer, which remains key to selecting appropriate patients and avoiding non-therapeutic surgeries, a commonly accepted definition is urgently needed to standardize practice, monitor outcomes, and improve the quality of research.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/bjsopen\/zraf070","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:14:57Z","timestamp":1747818897000},"source":"Crossref","is-referenced-by-count":8,"title":["The evolving concept of conversion surgery for upfront unresectable upper gastrointestinal and hepato-pancreato-biliary cancers: comprehensive review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-7114","authenticated-orcid":false,"given":"Giampaolo","family":"Perri","sequence":"first","affiliation":[{"name":"Hepato-pancreato-biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua , Padua ,","place":["Italy"]},{"name":"Department of General Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Maggiore Hospital , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Engstrand","sequence":"additional","affiliation":[{"name":"Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin D","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan F C","family":"Bronzwaer","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-4164","authenticated-orcid":false,"given":"Tiuri E","family":"Kroese","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-1772","authenticated-orcid":false,"given":"Biying","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belkacem","family":"Acidi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vitale","sequence":"additional","affiliation":[{"name":"Hepato-pancreato-biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hop S","family":"Tran Cao","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-261X","authenticated-orcid":false,"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-8132","authenticated-orcid":false,"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Sparrelid","sequence":"additional","affiliation":[{"name":"Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-6968","authenticated-orcid":false,"given":"Matthew H G","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6824-4533","authenticated-orcid":false,"given":"Giovanni","family":"Marchegiani","sequence":"additional","affiliation":[{"name":"Hepato-pancreato-biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-0245","authenticated-orcid":false,"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[{"name":"Hepato-pancreato-biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2026040406132691800_zraf070-B1","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1245\/s10434-020-09425-2","article-title":"Salvage robot-assisted minimally invasive esophagectomy (RAMIE) for T4b esophageal cancer after definitive chemoradiotherapy","volume":"28","author":"Defize","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B2","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1245\/s10434-024-16490-4","article-title":"Outcomes of salvage surgery for esophageal carcinoma: a nationwide cohort study from the Dutch Upper GI Cancer Audit","volume":"32","author":"Visser","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-031-39086-9_9","volume-title":"Esophageal Cancer: Diagnosis and Treatment","author":"Martiarena","year":"2023"},{"key":"2026040406132691800_zraf070-B4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clon.2014.06.001","article-title":"Definitive chemoradiotherapy for oesophageal cancer\u2014a promising start on an exciting journey","volume":"26","author":"Rackley","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026040406132691800_zraf070-B5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1245\/s10434-019-07654-8","article-title":"A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer","volume":"27","author":"Yokota","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B6","first-page":"423","article-title":"Implantation peritoneal carcinomatosis of ovarian origin","volume":"7","author":"Sampson","year":"1931","journal-title":"Am J Pathol"},{"key":"2026040406132691800_zraf070-B7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cancers14010060","article-title":"Peritoneal metastasis: current status and treatment options","volume":"14","author":"Roth","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B8","author":"(IKNL) IKN"},{"key":"2026040406132691800_zraf070-B9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026040406132691800_zraf070-B11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2022.06.012","article-title":"Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study","volume":"173","author":"Kroese","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026040406132691800_zraf070-B12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026040406132691800_zraf070-B13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","article-title":"Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma","volume":"108","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026040406132691800_zraf070-B14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","article-title":"The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI","volume":"17","author":"Al-Batran","year":"2017","journal-title":"BMC Cancer"},{"key":"2026040406132691800_zraf070-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejso.2022.09.012","article-title":"Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer","volume":"49","author":"Kroese","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2026040406132691800_zraf070-B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","article-title":"Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe","volume":"185","author":"Kroese","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026040406132691800_zraf070-B17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.crad.2014.07.017","article-title":"Imaging of oesophageal cancer with FDG-PET\/CT and MRI","volume":"70","author":"van Rossum","year":"2015","journal-title":"Clin Radiol"},{"key":"2026040406132691800_zraf070-B18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2026040406132691800_zraf070-B19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bjc.6604200","article-title":"Staging investigations for oesophageal cancer: a meta-analysis","volume":"98","author":"van Vliet","year":"2008","journal-title":"Br J Cancer"},{"key":"2026040406132691800_zraf070-B20","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1097\/JS9.0000000000001236","article-title":"Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"2026040406132691800_zraf070-B21","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1245\/s10434-021-11249-7","article-title":"Phase II prospective, open-label randomized controlled trial comparing standard of care chemotherapy with and without sequential cytoreductive interventions for patients with oligometastatic foregut adenocarcinoma and undetectable circulating tumor deoxyribose nucleic acid (ctDNA) levels","volume":"29","author":"Dhiman","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B23","doi-asserted-by":"crossref","first-page":"109679","DOI":"10.1016\/j.radonc.2023.109679","article-title":"Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial","volume":"184","author":"Zhao","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026040406132691800_zraf070-B24","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B25","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026040406132691800_zraf070-B26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","article-title":"Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study","volume":"168","author":"Willmann","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026040406132691800_zraf070-B27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"key":"2026040406132691800_zraf070-B29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12885-023-10773-x","article-title":"Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)","volume":"23","author":"Cui","year":"2023","journal-title":"BMC Cancer"},{"key":"2026040406132691800_zraf070-B30","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","article-title":"Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials","volume":"30","author":"Green","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ags3.12515","article-title":"International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1)","volume":"6","author":"Yoshida","year":"2022","journal-title":"Ann Gastroenterol Surg"},{"key":"2026040406132691800_zraf070-B32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1186\/s12885-018-4998-x","article-title":"Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy","volume":"18","author":"Beom","year":"2018","journal-title":"BMC Cancer"},{"key":"2026040406132691800_zraf070-B33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.21147\/j.issn.1000-9604.2019.01.13","article-title":"Risk-stratification model to select conversion surgery for advanced gastric cancer patients","volume":"31","author":"Nie","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"2026040406132691800_zraf070-B34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/cancers12010086","article-title":"Conversion surgery in metastatic gastric cancer and cancer dormancy as a prognostic biomarker","volume":"12","author":"Choe","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B35","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00432-021-03516-7","article-title":"Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis","volume":"147","author":"Ohnuma","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026040406132691800_zraf070-B36","doi-asserted-by":"crossref","first-page":"107314","DOI":"10.1016\/j.ejso.2023.107314","article-title":"Treatment strategy for successful conversion surgery in clinical stage IVB gastric cancer","volume":"50","author":"Hojo","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"2026040406132691800_zraf070-B37","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1245\/s10434-015-4422-6","article-title":"Prognostic role of conversion surgery for unresectable gastric cancer","volume":"22","author":"Fukuchi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijsu.2018.04.016","article-title":"Conversion surgery for gastric cancer: a cohort study from a Western center","volume":"53","author":"Morgagni","year":"2018","journal-title":"Int J Surg"},{"key":"2026040406132691800_zraf070-B39","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.7150\/jca.35527","article-title":"Long-term results of conversion therapy for initially unresectable gastric cancer: analysis of 122 patients at the National Cancer Center in China","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"2026040406132691800_zraf070-B40","doi-asserted-by":"crossref","first-page":"17126","DOI":"10.1002\/cam4.6362","article-title":"Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: a propensity score matching analysis","volume":"12","author":"Fang","year":"2023","journal-title":"Cancer Med"},{"key":"2026040406132691800_zraf070-B41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12957-021-02351-x","article-title":"Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology","volume":"19","author":"Valletti","year":"2021","journal-title":"World J Surg Oncol"},{"key":"2026040406132691800_zraf070-B42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00595-014-0979-0","article-title":"The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy","volume":"45","author":"Aizawa","year":"2015","journal-title":"Surg Today"},{"key":"2026040406132691800_zraf070-B43","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/cancers15245794","article-title":"Neoadjuvant chemotherapy followed by gastrectomy for cytology-positive gastric cancer without any other non-curative factors in a western setting: an international Eastern European cohort study","volume":"15","author":"Bausys","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B44","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s11605-018-3983-7","article-title":"Conversion surgery for gastric cancer with peritoneal metastasis based on the diagnosis of second-look staging laparoscopy","volume":"23","author":"Nakamura","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"2026040406132691800_zraf070-B45","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B46","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases","volume":"29","author":"Chia","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B47","author":"Tempero"},{"key":"2026040406132691800_zraf070-B48","doi-asserted-by":"crossref","first-page":"17251726","DOI":"10.1245\/s10434-009-0409-5","article-title":"AHPBA\/SSO\/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference","volume":"16","author":"Vauthey","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B49","author":"Das"},{"key":"2026040406132691800_zraf070-B50","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B51","volume-title":"General Rules for the Study of Pancreatic Cancer","author":"Japan Pancreas Society","year":"2016","edition":"7th edn"},{"key":"2026040406132691800_zraf070-B52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026040406132691800_zraf070-B53","doi-asserted-by":"crossref","first-page":"e087","DOI":"10.1097\/AS9.0000000000000087","article-title":"Resectability of pancreatic cancer is in the eye of the observer: a multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria","volume":"2","author":"Giannone","year":"2021","journal-title":"Ann Surg Open"},{"key":"2026040406132691800_zraf070-B54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"2026040406132691800_zraf070-B55","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.pan.2023.06.005","article-title":"\u2018Conversion surgery\u2019 for locally advanced pancreatic cancer: a position paper by the Study Group at the Joint Meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022","volume":"23","author":"Oba","year":"2023","journal-title":"Pancreatology"},{"key":"2026040406132691800_zraf070-B56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"2026040406132691800_zraf070-B57","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/SLA.0000000000006248","article-title":"REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer","volume":"280","author":"Boggi","year":"2024","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B59","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s13304-024-01860-0","article-title":"REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives","volume":"76","author":"Boggi","year":"2024","journal-title":"Updates Surg"},{"key":"2026040406132691800_zraf070-B60","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"2026040406132691800_zraf070-B61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2026040406132691800_zraf070-B62","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel+gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B63","doi-asserted-by":"crossref","first-page":"dju011","DOI":"10.1093\/jnci\/dju011","article-title":"Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy","volume":"106","author":"Sohal","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026040406132691800_zraf070-B64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MPA.0000000000000447","article-title":"Clinicopathological features of 15 occult and 178 clinical pancreatic ductal adenocarcinomas in 8339 autopsied elderly patients","volume":"45","author":"Matsuda","year":"2016","journal-title":"Pancreas"},{"key":"2026040406132691800_zraf070-B68","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"2026040406132691800_zraf070-B69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B70","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B71","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026040406132691800_zraf070-B72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","article-title":"Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"2026040406132691800_zraf070-B73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B74","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","article-title":"Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial","volume":"23","author":"van Dam","year":"2023","journal-title":"BMC Cancer"},{"issue":"Suppl 16","key":"2026040406132691800_zraf070-B75","doi-asserted-by":"crossref","first-page":"TPS4204","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4204","article-title":"Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer","volume":"41","author":"Chawla","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B76","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1245\/s10434-008-9844-y","article-title":"Survival after pancreatectomy with major arterial resection and reconstruction","volume":"15","author":"Stitzenberg","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11605-007-0296-7","article-title":"Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival","volume":"12","author":"Allendorf","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2026040406132691800_zraf070-B78","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1245\/s10434-022-11503-6","article-title":"Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study","volume":"29","author":"Ushida","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/SLA.0000000000003301","article-title":"Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience","volume":"273","author":"Rangelova","year":"2021","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 \u00b1 trial","volume":"197","author":"Fietkau","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"2026040406132691800_zraf070-B81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B82","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B83","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"2026040406132691800_zraf070-B84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000005666","article-title":"Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study","volume":"278","author":"Seelen","year":"2023","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026040406132691800_zraf070-B86","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1245\/s10434-020-08427-4","article-title":"The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer","volume":"27","author":"Perri","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1245\/s10434-021-10663-1","article-title":"Anatomic criteria determine resectability in locally advanced pancreatic cancer","volume":"29","author":"Gemenetzis","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B88","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/SLA.0000000000003442","article-title":"Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer","volume":"273","author":"Perri","year":"2021","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s12149-021-01629-0","article-title":"The role of FDG PET\/CT or PET\/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review","volume":"35","author":"Evangelista","year":"2021","journal-title":"Ann Nucl Med"},{"key":"2026040406132691800_zraf070-B90","first-page":"PO.19.00001","article-title":"Computed tomography-based biomarker outcomes in a prospective trial of preoperative FOLFIRINOX and chemoradiation for borderline resectable pancreatic cancer","volume":"3","author":"Koay","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2026040406132691800_zraf070-B91","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hpb.2021.09.004","article-title":"Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma","volume":"24","author":"Daamen","year":"2022","journal-title":"HPB (Oxford)"},{"key":"2026040406132691800_zraf070-B92","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026040406132691800_zraf070-B93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B94","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/cncr.34273","article-title":"Preoperative therapy for pancreatic adenocarcinoma\u2014precision beyond anatomy","volume":"128","author":"Seo","year":"2022","journal-title":"Cancer"},{"key":"2026040406132691800_zraf070-B95","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B96","doi-asserted-by":"crossref","first-page":"8244","DOI":"10.1038\/s41598-022-12214-4","article-title":"The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer","volume":"12","author":"Catalano","year":"2022","journal-title":"Sci Rep"},{"key":"2026040406132691800_zraf070-B97","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s11605-012-1923-5","article-title":"Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma","volume":"16","author":"Peng","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"2026040406132691800_zraf070-B98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-020-6690-1","article-title":"Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study","volume":"20","author":"Garnier","year":"2020","journal-title":"BMC Cancer"},{"key":"2026040406132691800_zraf070-B99","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ejso.2019.06.004","article-title":"Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases","volume":"45","author":"Suker","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026040406132691800_zraf070-B100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","article-title":"Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients","volume":"237","author":"Gudmundsdottir","year":"2023","journal-title":"J Am Coll Surg"},{"key":"2026040406132691800_zraf070-B101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00330-023-10069-5","article-title":"MRI with DWI improves detection of liver metastasis and selection of surgical candidates with pancreatic cancer: a systematic review and meta-analysis","volume":"34","author":"Altmayer","year":"2024","journal-title":"Eur Radiol"},{"key":"2026040406132691800_zraf070-B102","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/bjs\/znac363","article-title":"Pancreatectomy with resection and reconstruction of the superior mesenteric artery","volume":"110","author":"Boggi","year":"2023","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B103","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1097\/JS9.0000000000000971","article-title":"Postoperative results, learning curve, and outcomes of pancreatectomy with arterial resection: a single-center retrospective cohort study on 236 procedures","volume":"110","author":"Napoli","year":"2024","journal-title":"Int J Surg"},{"key":"2026040406132691800_zraf070-B104","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.surg.2020.08.030","article-title":"Periarterial divestment in pancreatic cancer surgery","volume":"169","author":"Diener","year":"2021","journal-title":"Surgery"},{"key":"2026040406132691800_zraf070-B105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jamcollsurg.2021.02.020","article-title":"Survival after margin-positive resection in the era of modern chemotherapy for pancreatic cancer: do patients still benefit?","volume":"233","author":"Arrington","year":"2021","journal-title":"J Am Coll Surg"},{"key":"2026040406132691800_zraf070-B106","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/SLA.0b013e318263da2f","article-title":"Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a \u2018true\u2019 R0 resection?","volume":"257","author":"Konstantinidis","year":"2013","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B107","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.21037\/jgo-20-379","article-title":"Can local ablative techniques replace surgery for locally advanced pancreatic cancer?","volume":"12","author":"Heger","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"2026040406132691800_zraf070-B108","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B109","doi-asserted-by":"crossref","first-page":"102067","DOI":"10.1016\/j.esmoop.2023.102067","article-title":"Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus","volume":"8","author":"Leonhardt","year":"2023","journal-title":"ESMO Open"},{"key":"2026040406132691800_zraf070-B110","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1097\/SLA.0000000000005481","article-title":"Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer","volume":"277","author":"Hank","year":"2023","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B111","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026040406132691800_zraf070-B112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13059-021-02363-6","article-title":"Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways","volume":"22","author":"Ho","year":"2021","journal-title":"Genome Biol"},{"issue":"Suppl 3","key":"2026040406132691800_zraf070-B113","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.2024.42.3_suppl.603","article-title":"Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): results of a multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani","year":"2024","journal-title":"J Hepatol"},{"key":"2026040406132691800_zraf070-B115","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy","volume":"72","author":"Vitale","year":"2020","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B116","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026040406132691800_zraf070-B117","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B118","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2026040406132691800_zraf070-B119","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026040406132691800_zraf070-B120","doi-asserted-by":"crossref","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"2026040406132691800_zraf070-B121","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2026040406132691800_zraf070-B122","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/lt.20526","article-title":"A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation","volume":"11","author":"Yao","year":"2005","journal-title":"Liver Transpl"},{"key":"2026040406132691800_zraf070-B123","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B124","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B125","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"key":"2026040406132691800_zraf070-B126","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","article-title":"Alpha-fetoprotein decrease from >1,000 to <500 ng\/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes","volume":"69","author":"Mehta","year":"2019","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B127","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30879","article-title":"National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time","volume":"71","author":"Mehta","year":"2020","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B128","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.30570","article-title":"Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis of the all-comers protocol","volume":"70","author":"Sinha","year":"2019","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B129","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s11605-013-2229-y","article-title":"Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria","volume":"17","author":"Lei","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"2026040406132691800_zraf070-B130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/bjs.7561","article-title":"Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria","volume":"98","author":"Gordon-Weeks","year":"2011","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B131","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jamcollsurg.2016.12.020","article-title":"Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions","volume":"224","author":"Chapman","year":"2017","journal-title":"J Am Coll Surg"},{"key":"2026040406132691800_zraf070-B132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00270-012-0458-1","article-title":"Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies","volume":"36","author":"Bova","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026040406132691800_zraf070-B133","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tri.13337","article-title":"Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence\u2014a retrospective study","volume":"32","author":"Toso","year":"2019","journal-title":"Transpl Int"},{"key":"2026040406132691800_zraf070-B134","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026040406132691800_zraf070-B135","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/lt.20837","article-title":"Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma","volume":"12","author":"Otto","year":"2006","journal-title":"Liver Transpl"},{"key":"2026040406132691800_zraf070-B136","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/liv.12966","article-title":"Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy","volume":"36","author":"Finkenstedt","year":"2016","journal-title":"Liver Int"},{"key":"2026040406132691800_zraf070-B137","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3390\/cancers13102406","article-title":"Sustained complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or \u2018wait and see\u2019 strategy?","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B138","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.3390\/cancers14205102","article-title":"Downstaging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes","volume":"14","author":"Di Martino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B139","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/ajt.13408","article-title":"A multistep, consensus-based approach to organ allocation in liver transplantation: toward a \u2018blended principle model\u2019","volume":"15","author":"Cillo","year":"2015","journal-title":"Am J Transplant"},{"key":"2026040406132691800_zraf070-B140","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/liv.13755","article-title":"Specific issues concerning the management of patients on the waiting list and after liver transplantation","volume":"38","author":"Burra","year":"2018","journal-title":"Liver Int"},{"key":"2026040406132691800_zraf070-B141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2023.10.029","article-title":"Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC)\u2014part I\u2014surgical treatments","volume":"56","author":"Cabibbo","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026040406132691800_zraf070-B142","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2026040406132691800_zraf070-B143","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.28998","article-title":"Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit","volume":"65","author":"Cillo","year":"2017","journal-title":"Hepatology"},{"key":"2026040406132691800_zraf070-B144","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"Suppl 1","key":"2026040406132691800_zraf070-B145","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.jhep.2015.02.007","article-title":"Liver cancer: approaching a personalized care","volume":"62","author":"Bruix","year":"2015","journal-title":"J Hepatol"},{"key":"2026040406132691800_zraf070-B146","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"2026040406132691800_zraf070-B147","doi-asserted-by":"crossref","first-page":"930868","DOI":"10.3389\/fonc.2022.930868","article-title":"Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"2026040406132691800_zraf070-B148","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"2026040406132691800_zraf070-B149","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1245\/s10434-023-13510-7","article-title":"Intersurgeon variability in local treatment planning for patients with initially unresectable colorectal cancer liver metastases: analysis of the liver expert panel of the Dutch colorectal cancer group","volume":"30","author":"Bond","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/SLA.0000000000004331","article-title":"Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice?","volume":"272","author":"Ignatavicius","year":"2020","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B151","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?","volume":"27","author":"Adam","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B152","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/hpb.12159","article-title":"Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases","volume":"16","author":"Devaud","year":"2014","journal-title":"HPB (Oxford)"},{"key":"2026040406132691800_zraf070-B153","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/bjs\/znaa145","article-title":"Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study","volume":"108","author":"Isoniemi","year":"2021","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B154","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jamcollsurg.2019.08.1445","article-title":"Outcomes of resectability assessment of the Dutch Colorectal Cancer Group liver metastases expert panel","volume":"229","author":"Huiskens","year":"2019","journal-title":"J Am Coll Surg"},{"key":"2026040406132691800_zraf070-B155","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/bjs.9285","article-title":"Variation in referral practice for patients with colorectal cancer liver metastases","volume":"100","author":"Young","year":"2013","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B156","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1245\/s10434-010-1304-9","article-title":"Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC)","volume":"17","author":"Ksienski","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B157","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1634\/theoncologist.2017-0028","article-title":"The impact of a hepatobiliary multidisciplinary team assessment in patients with colorectal cancer liver metastases: a population-based study","volume":"22","author":"Engstrand","year":"2017","journal-title":"Oncologist"},{"key":"2026040406132691800_zraf070-B158","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ejso.2016.03.031","article-title":"Clinical outcomes for patients with liver-limited metastatic colorectal cancer: arguing the case for specialist hepatobiliary multidisciplinary assessment","volume":"42","author":"Thillai","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"2026040406132691800_zraf070-B159","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2016.10.026","article-title":"Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands","volume":"71","author":"\u2019t Lam-Boer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026040406132691800_zraf070-B160","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/bjs.8835","article-title":"Effect of specialist decision-making on treatment strategies for colorectal liver metastases","volume":"99","author":"Jones","year":"2012","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B161","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.suronc.2020.09.024","article-title":"The value of a dedicated multidisciplinary expert panel to assess treatment strategy in patients suffering from colorectal cancer liver metastases","volume":"35","author":"Hellingman","year":"2020","journal-title":"Surg Oncol"},{"key":"2026040406132691800_zraf070-B162","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s10147-018-01393-8","article-title":"mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival","volume":"24","author":"Yasuno","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2026040406132691800_zraf070-B163","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/SLA.0b013e31819a0486","article-title":"Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil\/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases","volume":"249","author":"Masi","year":"2009","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B164","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12957-016-0807-7","article-title":"Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases","volume":"14","author":"Kawamura","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2026040406132691800_zraf070-B166","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","article-title":"A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases","volume":"19","author":"Lam","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B167","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2020.09.037","article-title":"Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: a systematic review","volume":"141","author":"Bolhuis","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026040406132691800_zraf070-B168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B169","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B170","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026040406132691800_zraf070-B171","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1245\/s10434-013-3009-3","article-title":"Conversion to complete resection and\/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution","volume":"20","author":"Ammori","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B172","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential","volume":"117","author":"Pak","year":"2018","journal-title":"J Surg Oncol"},{"key":"2026040406132691800_zraf070-B173","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B174","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/bjs.1800730917","article-title":"Determinants of survival in liver resection for colorectal secondaries","volume":"73","author":"Ekberg","year":"1986","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B175","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I","article-title":"Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran\u00e7aise de Chirurgie","volume":"77","author":"Nordlinger","year":"1996","journal-title":"Cancer"},{"key":"2026040406132691800_zraf070-B176","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.2007-0142","article-title":"Expanding criteria for resectability of colorectal liver metastases","volume":"13","author":"Pawlik","year":"2008","journal-title":"Oncologist"},{"key":"2026040406132691800_zraf070-B177","doi-asserted-by":"crossref","first-page":"zrac097","DOI":"10.1093\/bjsopen\/zrac097","article-title":"Impact of post-hepatectomy liver failure on morbidity and short- and long-term survival after major hepatectomy","volume":"6","author":"Baumgartner","year":"2022","journal-title":"BJS Open"},{"key":"2026040406132691800_zraf070-B178","doi-asserted-by":"crossref","first-page":"zrac142","DOI":"10.1093\/bjsopen\/zrac142","article-title":"Current evidence on posthepatectomy liver failure: comprehensive review","volume":"6","author":"Sparrelid","year":"2022","journal-title":"BJS Open"},{"key":"2026040406132691800_zraf070-B179","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000335713","article-title":"How much remnant is enough in liver resection?","volume":"29","author":"Guglielmi","year":"2012","journal-title":"Dig Surg"},{"key":"2026040406132691800_zraf070-B180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1091-255X(02)00370-0","article-title":"Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection","volume":"7","author":"Shoup","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"2026040406132691800_zraf070-B181","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/0016-5085(85)90005-8","article-title":"In vivo hepatic volume determination using sonography and computed tomography. Validation and a comparison of the two techniques","volume":"88","author":"Van Thiel","year":"1985","journal-title":"Gastroenterology"},{"key":"2026040406132691800_zraf070-B182","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/SLA.0000000000000213","article-title":"Measured versus estimated total liver volume to preoperatively assess the adequacy of the future liver remnant: which method should we use?","volume":"258","author":"Ribero","year":"2013","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B183","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.surg.2019.05.003","article-title":"Accuracy of estimated total liver volume formulas before liver resection","volume":"166","author":"Olthof","year":"2019","journal-title":"Surgery"},{"key":"2026040406132691800_zraf070-B184","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1245\/s10434-006-9045-5","article-title":"Improving resectability of hepatic colorectal metastases: expert consensus statement","volume":"13","author":"Abdalla","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B185","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/SLA.0b013e3181b674df","article-title":"Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry","volume":"250","author":"Kishi","year":"2009","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B186","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00000658-200012000-00006","article-title":"Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors","volume":"232","author":"Adam","year":"2000","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B187","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9610(02)01373-9","article-title":"One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases","volume":"185","author":"Jaeck","year":"2003","journal-title":"Am J Surg"},{"key":"2026040406132691800_zraf070-B188","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ags3.12465","article-title":"Optimal patient selection for successful two-stage hepatectomy of bilateral colorectal liver metastases","volume":"5","author":"Imai","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"key":"2026040406132691800_zraf070-B189","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/SLA.0b013e31824856f5","article-title":"Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings","volume":"255","author":"Schnitzbauer","year":"2012","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B190","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/SLA.0000000000001450","article-title":"Prediction of mortality after ALPPS stage-1: an analysis of 320 patients from the international ALPPS registry","volume":"262","author":"Schadde","year":"2015","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B191","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000480100","article-title":"A comparison of pitfalls after ALPPS stage 1 or portal vein embolization in small-for-size setting hepatectomies","volume":"33","author":"Schnitzbauer","year":"2017","journal-title":"Visc Med"},{"key":"2026040406132691800_zraf070-B192","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/SLA.0000000000002511","article-title":"ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis","volume":"267","author":"Sandstr\u00f6m","year":"2018","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B193","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.hpb.2018.11.010","article-title":"Avoiding postoperative mortality after ALPPS-development of a tumor-specific risk score for colorectal liver metastases","volume":"21","author":"Huiskens","year":"2019","journal-title":"HPB (Oxford)"},{"key":"2026040406132691800_zraf070-B194","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1007\/s00330-016-4291-9","article-title":"Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique","volume":"26","author":"Guiu","year":"2016","journal-title":"Eur Radiol"},{"key":"2026040406132691800_zraf070-B195","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00270-022-03176-1","article-title":"Dragon 1 protocol manuscript: training, accreditation, implementation and safety evaluation of portal and hepatic vein embolization (PVE\/HVE) to accelerate future liver remnant (FLR) hypertrophy","volume":"45","author":"Korenblik","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026040406132691800_zraf070-B196","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/SLA.0b013e3181557e47","article-title":"Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients","volume":"247","author":"Gold","year":"2008","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B197","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00268-019-05121-9","article-title":"Recurrence patterns after resection of colorectal liver metastasis are modified by perioperative systemic chemotherapy","volume":"44","author":"Buisman","year":"2020","journal-title":"World J Surg"},{"key":"2026040406132691800_zraf070-B198","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bjs\/znaa112","article-title":"Parenchyma-sparing vessel-guided major hepatectomy: nonsense or new paradigm in liver surgery?","volume":"108","author":"Torzilli","year":"2021","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B199","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?","volume":"261","author":"Dueland","year":"2015","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B201","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"2026040406132691800_zraf070-B202","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/SLA.0000000000002353","article-title":"Laparoscopic versus open resection for colorectal liver metastases: the OSLO-COMET randomized controlled trial","volume":"267","author":"Fretland","year":"2018","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/M20-4011","article-title":"Long-term oncologic outcomes after laparoscopic versus open resection for colorectal liver metastases: a randomized trial","volume":"174","author":"Aghayan","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026040406132691800_zraf070-B204","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1007\/s00464-022-09612-0","article-title":"Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis","volume":"36","author":"Ozair","year":"2022","journal-title":"Surg Endosc"},{"key":"2026040406132691800_zraf070-B205","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/cancers13112769","article-title":"Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an Amsterdam Colorectal Liver Met Registry (AmCORE) based study","volume":"13","author":"Dijkstra","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026040406132691800_zraf070-B206","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"2026040406132691800_zraf070-B207","doi-asserted-by":"crossref","first-page":"djx015","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026040406132691800_zraf070-B208","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamasurg.2013.1431","article-title":"Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases","volume":"148","author":"Karanicolas","year":"2013","journal-title":"JAMA Surg"},{"key":"2026040406132691800_zraf070-B209","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/SLA.0000000000000976","article-title":"Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes","volume":"260","author":"Faitot","year":"2014","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B210","doi-asserted-by":"crossref","first-page":"e114404","DOI":"10.1371\/journal.pone.0114404","article-title":"Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases","volume":"9","author":"Evrard","year":"2014","journal-title":"PLoS One"},{"key":"2026040406132691800_zraf070-B211","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/bjs.10159","article-title":"Single-stage resection and microwave ablation for bilobar colorectal liver metastases","volume":"103","author":"Philips","year":"2016","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B212","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejso.2020.08.018","article-title":"A new sequential treatment strategy for multiple colorectal liver metastases: planned incomplete resection and postoperative completion ablation for intentionally-untreated tumors under guidance of cross-sectional imaging","volume":"47","author":"Okuno","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"2026040406132691800_zraf070-B213","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.hpb.2021.03.014","article-title":"Short- and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for patients with multiple primarily unresectable colorectal liver metastases: a propensity matching analysis","volume":"23","author":"Liu","year":"2021","journal-title":"HPB (Oxford)"},{"key":"2026040406132691800_zraf070-B214","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02656736.2021.1892835","article-title":"Long-term outcome for colorectal liver metastases: combining hepatectomy with intraoperative ultrasound guided open microwave ablation versus hepatectomy alone","volume":"38","author":"Dai","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"2026040406132691800_zraf070-B215","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/bjs.10447","article-title":"Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases","volume":"104","author":"Imai","year":"2017","journal-title":"Br J Surg"},{"key":"2026040406132691800_zraf070-B216","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/02656736.2022.2086712","article-title":"Effectiveness and safety of ultrasound-guided high-intensity focused ultrasound ablation for the treatment of colorectal cancer liver metastases","volume":"39","author":"Yang","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"2026040406132691800_zraf070-B217","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s00464-020-07644-y","article-title":"HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial","volume":"35","author":"Yang","year":"2021","journal-title":"Surg Endosc"},{"key":"2026040406132691800_zraf070-B218","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1148\/radiol.2021203089","article-title":"Irreversible electroporation to treat unresectable colorectal liver metastases (COLDFIRE-2): a phase II, two-center, single-arm clinical trial","volume":"299","author":"Meijerink","year":"2021","journal-title":"Radiology"},{"key":"2026040406132691800_zraf070-B219","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11912-022-01248-6","article-title":"Microwave ablation, radiofrequency ablation, irreversible electroporation, and stereotactic ablative body radiotherapy for intermediate size (3\u20135 cm) unresectable colorectal liver metastases: a systematic review and meta-analysis","volume":"24","author":"Nieuwenhuizen","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026040406132691800_zraf070-B220","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"2026040406132691800_zraf070-B221","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"2026040406132691800_zraf070-B222","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026040406132691800_zraf070-B223","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2026040406132691800_zraf070-B224","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026040406132691800_zraf070-B225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2024.42.3_suppl.433","article-title":"Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: a multicenter phase II trial","volume":"42","author":"Franssen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B226","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1245\/s10434-021-11206-4","article-title":"Impact of gemcitabine plus S1 neoadjuvant chemotherapy on borderline resectable perihilar cholangiocarcinoma","volume":"29","author":"Matsuyama","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B227","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jhbp.1437","article-title":"Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea","volume":"31","author":"Yabushita","year":"2024","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2026040406132691800_zraf070-B228","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00423-025-03630-x","article-title":"Survival benefit of conversion surgery for initially unresectable biliary tract cancer: a systematic review and meta-analysis","volume":"410","author":"Zhou","year":"2025","journal-title":"Langenbecks Arch Surg"},{"key":"2026040406132691800_zraf070-B229","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B230","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026040406132691800_zraf070-B231","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"2026040406132691800_zraf070-B232","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"2026040406132691800_zraf070-B233","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3748\/wjg.v29.i13.1969","article-title":"Liver transplantation in the management of cholangiocarcinoma: evolution and contemporary advances","volume":"29","author":"Borakati","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026040406132691800_zraf070-B234","author":"University Hospital, Lille"},{"key":"2026040406132691800_zraf070-B235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1245\/s10434-023-14415-1","article-title":"Gastrectomy+cytoreductive surgery+HIPEC for gastric cancer with peritoneal dissemination (PERISCOPE II)","volume":"31","author":"Sarvestani","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026040406132691800_zraf070-B236","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/pp-2022-0111","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne","volume":"7","author":"Casella","year":"2022","journal-title":"Pleura Peritoneum"},{"key":"2026040406132691800_zraf070-B237","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1186\/s12885-021-08966-3","article-title":"Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil\/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC)","volume":"21","author":"Gebauer","year":"2021","journal-title":"BMC Cancer"},{"issue":"Suppl 16","key":"2026040406132691800_zraf070-B238","doi-asserted-by":"crossref","first-page":"TPS4207","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4207","article-title":"METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: multimodal surgical treatment versus systemic chemotherapy alone\u2014a prospective randomized controlled multicenter phase III trial","volume":"42","author":"Jo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B239","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jhbp.1135","article-title":"Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors","volume":"29","author":"Arita","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"Suppl 17","key":"2026040406132691800_zraf070-B240","doi-asserted-by":"crossref","first-page":"LBA3502","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3502","article-title":"Primary outcome analysis of the ORCHESTRA trial: a randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer","volume":"42","author":"Gootjes","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040406132691800_zraf070-B241","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Ilyas","year":"2017","journal-title":"J Hepatol"},{"key":"2026040406132691800_zraf070-B242","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4251\/wjgo.v13.i5.332","article-title":"Liquid biopsy in cholangiocarcinoma: current status and future perspectives","volume":"13","author":"Rompianesi","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"2026040406132691800_zraf070-B243","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12909-023-04698-z","article-title":"Revolutionizing healthcare: the role of artificial intelligence in clinical practice","volume":"23","author":"Alowais","year":"2023","journal-title":"BMC Med Educ"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/4\/zraf070\/63710153\/zraf070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/4\/zraf070\/63710153\/zraf070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:14:09Z","timestamp":1775297649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zraf070\/8195135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":243,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zraf070","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,1]]},"article-number":"zraf070"}}